Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Navignostics AG logo — Finding the Right Drug for Each Patient

Navignostics AG

Finding the Right Drug for Each Patient

Founded 2022 Switzerland Horgen, Switzerland 15 employees Seed Total: $8.50M Biotechnology, Health Care +4

General Information

Company Name Navignostics AG
Founded Year 2022
Location Switzerland Horgen, Switzerland
Employees 15
Industries Biotechnology, Health Care, Health and Wellness +3
Funding Stage Seed
Social

BounceWatch is an independent company data service, not affiliated with Navignostics AG. To contact Navignostics AG, visit navignostics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Navignostics AG compare?

A PDF of Navignostics AG and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Navignostics AG soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Navignostics AG

Navignostics AG is a Swiss-based biotechnology startup founded in 2022 with the slogan "Finding the Right Drug for Each Patient." The company's mission revolves around identifying the ideal treatment for cancer patients using spatial single-cell proteomics to characterize tumors. This approach enables Navignostics to offer personalized cancer treatment by matching the most effective drug with each patient's specific tumor, ultimately reducing suffering. Additionally, the company's robust technology and advanced data analytics not only facilitate precision cancer diagnostics for patients but also provide valuable insights for the development of companion diagnostics for pharma and biotech partners. The startup recently secured a Fr.7.50M Seed Round investment on 09 November 2022 from notable investors including Ventura BioMed Investors, Zürcher Kantonal Bank, Bruker, and Think.Health. With its focus on revolutionizing cancer treatment through personalized medicine, Navignostics AG aims to make a significant impact by making more drugs available and identifying the right treatment for every patient.

Business keywords: Precision Medicine, Cancer Treatment, Tumor Characterization, Single-cell Proteomics, Companion Diagnostics, Drug Development, Pharma Partnerships, Biotech Partnerships

Services & Products

tumor analysis
biomarker identification
drug targeting

Target Customers

clinicians researchers drug developers

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round Fr.7.50M 4
Ventura BioMed Investors
Ventura BioMed Investors, Zürcher Kantonal Bank +2
09 Nov 2022
Convertible Note Fr.1.00M 1
UZH Foundation – Die Stiftung der Universität Zürich
UZH Foundation – Die Stiftung der Universität Zürich
29 Aug 2022

Navignostics AG Alternatives & Competitors

View All Alternatives
Navignostics AG vs
Talus Bio
Talus Bio United States

Gene regulator profiling in live cells for drug development

Grant
24 employees
Biotechnology, Health Care
Navignostics AG vs
BioReperia
BioReperia Sweden

Accelerating drug discovery and predicting the best cancer treatment for you!

Series A
19 employees
Biopharma, Biotechnology
Navignostics AG vs
Genomate Health
Genomate Health United States

The right drug. The first time. Every time.™ Pioneering Digital Drug Assignment for Precision Onco...

Seed
29 employees
Biotechnology, Health Care
View all alternatives

FAQ About Navignostics AG

Finding the Right Drug for Each Patient
Navignostics AG was founded in 2022.
Navignostics AG is headquartered in Horgen, Switzerland.
Navignostics AG operates in Biotechnology, Health Care, Health and Wellness, Life Sciences, Medical Devices and Clean Energy. Its work centres on Precision Medicine, Cancer Treatment, Tumor Characterization and Single-cell Proteomics. Its customers include clinicians, researchers and drug developers.
Navignostics AG has approximately 15 employees.
Navignostics AG has completed 2 funding rounds, raising a total of $8.50M. The latest funding stage is Seed.
Navignostics AG offers: tumor analysis, biomarker identification, drug targeting.
Top alternatives and competitors to Navignostics AG include Talus Bio, BioReperia, Genomate Health, Oniria Therapeutics, GeneCast Biotechnology Co., Ltd.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Navignostics AG and Talus Bio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Navignostics AG, https://bouncewatch.com/company/navignostics-ag, updated 13 April 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout